Safety, efficacy, and dosing of recombinant human bone morphogenetic protein-2 for posterior cervical and cervicothoracic instrumented fusion with a minimum 2-year follow-up.
about
A consensus statement regarding the utilization of BMP in spine surgeryPrevalence of adjacent segment disease following cervical spine surgery: A PRISMA-compliant systematic review and meta-analysis.Long-Segment Fusion for Adult Spinal Deformity Correction Using Low-Dose Recombinant Human Bone Morphogenetic Protein-2: A Retrospective Review of Fusion Rates.Bone substitutes and expanders in Spine Surgery: A review of their fusion efficacies.Cyst-Like Osteolytic Formations in Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Augmented Sheep Spinal Fusion.
P2860
Safety, efficacy, and dosing of recombinant human bone morphogenetic protein-2 for posterior cervical and cervicothoracic instrumented fusion with a minimum 2-year follow-up.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Safety, efficacy, and dosing o ...... th a minimum 2-year follow-up.
@ast
Safety, efficacy, and dosing o ...... th a minimum 2-year follow-up.
@en
type
label
Safety, efficacy, and dosing o ...... th a minimum 2-year follow-up.
@ast
Safety, efficacy, and dosing o ...... th a minimum 2-year follow-up.
@en
prefLabel
Safety, efficacy, and dosing o ...... th a minimum 2-year follow-up.
@ast
Safety, efficacy, and dosing o ...... th a minimum 2-year follow-up.
@en
P2093
P2860
P1433
P1476
Safety, efficacy, and dosing o ...... th a minimum 2-year follow-up.
@en
P2093
Brian J Williams
Christopher I Shaffrey
D Kojo Hamilton
Daniel R Chernavvsky
Davis L Reames
Justin S Smith
P2860
P304
103-11; discussion 111
P356
10.1227/NEU.0B013E318214A9B1
P407
P577
2011-07-01T00:00:00Z